Yamaguchi M, Hirayama F, Kanai M, Sato N, Fukazawa K, Yamashita K, Sawada K, Koike T, Kuwabara M, Ikeda H, Ikebuchi K
Hokkaido Red Cross Blood Center, Sapporo, Japan.
Exp Hematol. 2001 Feb;29(2):174-82. doi: 10.1016/s0301-472x(00)00653-6.
In an attempt to maintain and expand human stem cells, many investigators have used xenogeneic, especially murine, stromal cells and fetal calf serum. Because of the possible transmission of infectious diseases, however, the safety of the delivery of grafts expanded in culture using xenogeneic cells and serum has been debated. Using primary human marrow stromal cells, we established a novel serum-free culture system to expand human primitive progenitors and transplantable stem cells.
Cord blood CD34(+) cells were cultured on a monolayer of human primary marrow stromal cells in the presence of thrombopoietin (TPO), flt3/flk2 ligand (FL), and/or stem cell factor (SCF) under serum-free conditions. After 2 or 4 weeks of culture, cells were examined for clonogenic progenitors and severe combined immunodeficient disorder (SCID) mouse-reconstituting cells (SRC).
In the presence of TPO, FL, and SCF, marrow stromal cells supported more than a 100- and 1,000-fold expansion of CD34(+) cells and colony-forming units in culture after 2 and 4 weeks of incubation, respectively. In addition, cobblestone area-forming cells were expanded more than 18- and 60-fold after 2 and 4 weeks of culture, respectively. Furthermore, SRC assay demonstrated augmented engraftment by cultured cells.
This ex vivo expansion system should prove valuable in clinical settings in which stromal cells are available from recipients or stem cell donors.
为了维持和扩增人类干细胞,许多研究人员使用了异种的,尤其是鼠类的基质细胞和胎牛血清。然而,由于可能传播传染病,使用异种细胞和血清在体外扩增的移植物的安全性一直存在争议。我们利用原代人骨髓基质细胞建立了一种新型无血清培养系统,以扩增人类原始祖细胞和可移植干细胞。
在无血清条件下,将脐血CD34(+)细胞接种于原代人骨髓基质细胞单层上,并添加血小板生成素(TPO)、fms样酪氨酸激酶3/胎儿肝激酶2配体(FL)和/或干细胞因子(SCF)进行培养。培养2或4周后,检测细胞的集落形成祖细胞和重症联合免疫缺陷病(SCID)小鼠重建细胞(SRC)。
在TPO、FL和SCF存在的情况下,骨髓基质细胞分别在培养2周和4周后,支持CD34(+)细胞和集落形成单位在培养物中扩增100倍以上和1000倍以上。此外,鹅卵石区域形成细胞在培养2周和4周后分别扩增了18倍和60倍以上。此外,SRC检测表明培养细胞的植入能力增强。
这种体外扩增系统在临床环境中应该是有价值的,在这种环境中,基质细胞可从受体或干细胞供体获得。